Healthcare Industry News: Parkinson’s disease
News Release - June 2, 2008
Banner Pharmacaps Receives FDA Approval for Amantadine Softgel Capsules
HIGH POINT, N.C.--(HSMN NewsFeed)--Banner Pharmacaps Inc., a leader in the pharmaceutical industry for the development of soft gelatin dosage form technology, announces that the US Food & Drug Administration granted approval for the Company’s Abbreviated New Drug Application (ANDA) for Amantadine Hydrochloride USP 100 mg soft gelatin capsules on May 29, 2008.Amantadine is indicated for the prophylaxis and treatment of signs and symptoms of infection in the respiratory tract caused by various strains of influenza A virus. Amantadine is also utilized in the treatment of Parkinson’s disease and drug-induced extrapyramidal reactions.
About Banner Pharmacaps Inc.
Banner Pharmacaps Inc. is a global drug delivery and specialty pharmaceutical company which is developing a proprietary portfolio of unique products and oral dosage forms that include the enhanced technologies of enteric and controlled release softgels, as well as Soflet® Gelcaps. Headquartered in High Point, North Carolina, Banner is committed to the research, development, and manufacture of quality healthcare products to serve our global community. Additional information about Banner is available at http://www.banpharm.com.
The parent company of Banner is VION N.V., an international food group that produces high-quality foodstuffs and ingredients for humans and animals. VION has annual sales of €7.1 Billion, with 15,150 employees worldwide. The head office of VION is in Son en Breugel, The Netherlands.
Source: Banner Pharmacaps
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
